These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

51 related articles for article (PubMed ID: 348309)

  • 21. A phase I study of paclitaxel, etoposide, and cisplatin in extensive stage small cell lung cancer.
    Kelly K; Pan Z; Wood ME; Murphy J; Bunn PA
    Clin Cancer Res; 1999 Nov; 5(11):3419-24. PubMed ID: 10589753
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cisplatin and etoposide alternating ifosfamide, vincristine, epirubicin in small cell lung cancer.
    Unsal M; Erturk D
    Saudi Med J; 2003 Jun; 24(6):628-31. PubMed ID: 12847592
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fractionated cyclophosphamide added to the IVAP regimen (idarubicin-vincristine-L-asparaginase-prednisone) could lower the risk of primary refractory disease in T-lineage but not B-lineage acute lymphoblastic leukemia: first results from a phase II clinical study.
    Bassan R; Pogliani E; Lerede T; Fabris P; Rossi G; Morandi S; Casula P; Lambertenghi-Deliliers G; Vespignani M; Izzi T; Coser P; Corneo G; Barbui T
    Haematologica; 1999 Dec; 84(12):1088-93. PubMed ID: 10586210
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intermittent high-dose cyclophosphamide with and without prednisolone: a study of the relationships between toxicity, response and survival in metastatic lung cancer.
    Thatcher N; Wagstaff J; Wilkinson P; Palmer M; Crowther D
    Cancer; 1982 Sep; 50(6):1051-6. PubMed ID: 7049346
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adjuvant cancer chemotherapy after resection of carcinoma of the lung.
    Shields TW; Humphrey EW; Eastridge CE; Keehn RJ
    Cancer; 1977 Nov; 40(5):2057-62. PubMed ID: 336178
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intensive cyclophosphamide (NSC-26271) therapy for solid tumors.
    Mullins GM; Colvin M
    Cancer Chemother Rep; 1975; 59(2 Pt 1):411-9. PubMed ID: 1097100
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High dose cyclophosphamide treatment of human oat cell xenografts in immune deprived mice.
    Evans BD; Smith IE; Millar JL
    Br J Cancer; 1983 Feb; 47(2):215-9. PubMed ID: 6297529
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serum cyclophosphamide activity in patients treated for small cell carcinoma of the lung.
    Sarpel SC; Lad T; Epstein RB
    J Clin Oncol; 1983 Jan; 1(1):29-32. PubMed ID: 6321670
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High dose cyclophosphamide therapy in solid tumors. Therapeutic, toxic, and immunosuppressive effects.
    Mullins GM; Anderson PN; Santos GW
    Cancer; 1975 Dec; 36(6):1950-8. PubMed ID: 128408
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Timed sequential chemotherapy of cytoxan-refractory multiple myeloma with cytoxan and adriamycin based on induced tumor proliferation.
    Karp JE; Humphrey RL; Burke PJ
    Blood; 1981 Mar; 57(3):468-75. PubMed ID: 7006709
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cell kinetic studies in patients with small cell carcinoma of the lung.
    Muggia FM; Krezoski SK; Hansen HH
    Cancer; 1974 Nov; 34(5):1683-90. PubMed ID: 4371944
    [No Abstract]   [Full Text] [Related]  

  • 32. Effect of administration schedule on the levan-cyclophosphamide combined treatment of Lewis lung carcinoma.
    Stark Y; Leibovici J; Wolman M
    Int J Immunopharmacol; 1983; 5(4):289-97. PubMed ID: 6629589
    [TBL] [Abstract][Full Text] [Related]  

  • 33. EST 0469B--comparison of high- and low-dose cyclophosphamide in human lung cancer.
    Hall TC; Pocock S; Brodovsky H; Horton J; Shnider BI; Colsky J; Oberfield RA
    Med Pediatr Oncol; 1978; 5(1):231-40. PubMed ID: 370535
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cyclophosphamide-induced lung damage in mice: protection by a small preliminary dose.
    Collis CH; Wilson CM; Jones JM
    Br J Cancer; 1980 Jun; 41(6):901-7. PubMed ID: 7426315
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pathology of high dose intermittent cyclophosphamide therapy.
    Slavin RE; Millan JC; Mullins GM
    Hum Pathol; 1975 Nov; 6(6):693-709. PubMed ID: 1183993
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Case of lung carcinoma treated with massive intravenous administration of Endoxan].
    Frontczak J
    Gruzlica; 1971 May; 39(5):431-2. PubMed ID: 5563839
    [No Abstract]   [Full Text] [Related]  

  • 37. Apparent cure of cancer with cyclophosphamide.
    Dark JF
    Br Med J; 1968 Oct; 4(5624):161-2. PubMed ID: 5681055
    [No Abstract]   [Full Text] [Related]  

  • 38. High tumour contamination of leukaphereses in patients with small cell carcinoma of the lung: a comparison of immunocytochemistry and RT-PCR.
    Perey L; Benhattar J; Peters R; Jaunin P; Leyvraz S
    Br J Cancer; 2001 Nov; 85(11):1713-21. PubMed ID: 11742493
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High-dose cyclophosphamide with autologous bone marrow rescue after conventional chemotherapy in the treatment of small cell lung carcinoma.
    Smith IE; Evans BD; Harland SJ; Robinson BA; Yarnold JR; Glees JG; Ford HT
    Cancer Chemother Pharmacol; 1985; 14(2):120-4. PubMed ID: 2982509
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intermittent high-dose cyclophosphamide chemotherapy for small cell carcinoma of the lung.
    Ettinger DS; Karp JE; Abeloff MD; Burke PJ; Braine HG
    Cancer Treat Rep; 1978 Mar; 62(3):413-24. PubMed ID: 348309
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.